| Profiling Program of Advanced/Metastatic Pancreatic Cancer Patients (NCT05380414) | Centre Leon Berard | 2022-07-01 |
| Quality of Life With Nutritional Supplementation in Patients With Locally Advanced/Metastatic Pancreatic Cancer. (NCT05360745) | Fundacion para la Excelencia y la Calidad de la Oncologia | 2022-06-29 |
| Liquid Biopsy and Pancreas Cancer: Detection of AXL(+) CTCs (CTC-AXL-PANC) (NCT05346536) | University Hospital, Montpellier | 2022-06-16 |
| Spleen Irradiation With Nanoliposomal Irinotecan Plus 5-FU and Leucovorin in Metastatic Pancreatic Adenocarcinoma (NCT05363007) | National Taiwan University Hospital | 2022-05-01 |
| The ASCEND Study: Gemcitabine and Nab-Paclitaxel With LSTA1 (Certepetide) or Placebo in Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma (NCT05042128) | Australasian Gastro-Intestinal Trials Group | 2022-04-13 |
| Nab-Paclitaxel + Cisplatin + Gemcitabine + TTF in pt. w/ Metastatic PAC (NCT04605913) | Mayo Clinic | 2022-04-01 |
| Prophylactic Administration of Neulapeg (Pegteograstim) in Patients With Locally Advanced or Metastatic Pancreatic Cancer Receiving the Modified FOLFIRINOX (NCT06353581) | Yonsei University | 2022-02-16 |
| A Phase 1 First-In-Human Study of the Anti-CD73 IPH5301 Alone or in Combination With Chemotherapy and Trastuzumab in Patients With Advanced Solid Tumors (NCT05143970) | Institut Paoli-Calmettes | 2022-01-21 |
| Efficacy of Gembrax Followed by Folfirinox Versus Folfirinox Alone in First Metastatic Line Pancreatic Cancer Patients (NCT05065801) | Institut du Cancer de Montpellier - Val d'Aurelle | 2022-01-11 |
| A Study of Donafenib Plus S-1 in Treating Patients With Metastatic Pancreatic Cancer After Chemotherapy With Nab-paclitaxel Plus Gemcitabine Regimen (NCT05138159) | Fudan University | 2021-12-01 |
| Atezolizumab + Cabozantinib in Patients w/ Metastatic, Refractory Pancreatic Cancer (NCT04820179) | University of Arizona | 2021-10-12 |
| Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer. (NCT04753879) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2021-09-29 |
| MesoPher/Mitazalimab-combination Therapy in Metastatic Pancreatic Disease (REACtiVe-2 Trial) (NCT05650918) | Joachim Aerts, MD PhD | 2021-08-30 |
| An Open-label, Uncontrolled Study of ONO-7913 and ONO-4538 in Combination With Modified FOLFIRINOX Therapy, the Standard of Care, as First-line Treatment in Patients With Metastatic Pancreatic Cancer (NCT06532344) | Ono Pharmaceutical Co., Ltd. | 2021-07-30 |
| Immune Checkpoint Inhibitor M7824 and the Immunocytokine M9241 in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Advanced Pancreas Cancer (NCT04327986) | National Cancer Institute (NCI) | 2021-06-15 |
| Anlotinib, Toripalimab and Nab-paclitaxel in Locally Advanced/Metastatic Pancreatic Cancer (NCT04718701) | The First Affiliated Hospital with Nanjing Medical University | 2021-04-01 |
| Single Patient Protocol for an NRG1 Fusion Positive Metastatic Pancreatic Cancer Patient Using Seribantumab (NCT04790695) | Ottawa Hospital Research Institute | 2021-03-29 |
| Flouro-Gem in Adenocarcinoma of the Pancreas (GEFLUPAN) (NCT04769414) | Menoufia University | 2021-02-20 |
| Good Choice of pALliative Chemotherapy to Patient With Pancreatic Cancer ; GemcitAbine Therapy vs FOLFORINOX therapY (NCT04789980) | Boryung Pharmaceutical Co., Ltd | 2021-01-29 |
| An Open-label, Uncontrolled Study of ONO-4578 and ONO-4538 in Combination With Standard-of-care Modified FOLFIRINOX (mFFX) or Gemcitabine Plus Nab-paclitaxel (GnP) Therapy as First-line Treatment in Patients With Metastatic Pancreatic Cancer (NCT06538207) | Ono Pharmaceutical Co., Ltd. | 2021-01-13 |
| SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells (NCT04150042) | General Oncology, Inc. | 2021-01-13 |
| Modified FOLFIRINOX Alternated With Biweekly Gemcitabine Plus Nab-Paclitaxel Untreated Pancreatic Cancer (NCT04672005) | Lyudmyla Berim | 2021-01-06 |
| First-in-human Study of the Theranostic Pair [68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G in Pancreatic Cancer (NCT04665947) | University of California, Davis | 2020-12-18 |
| Plerixafor and Cemiplimab in Metastatic Pancreatic Cancer (NCT04177810) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2020-11-16 |
| Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors (NCT04222413) | National Cancer Institute (NCI) | 2020-10-27 |
| Alpha Radiation Emitters Device for the Treatment of Advanced Pancreatic Cancer (NCT04002479) | Alpha Tau Medical LTD. | 2020-10-20 |
| Saltikva for Metastatic Pancreatic Cancer (NCT04589234) | Salspera LLC | 2020-10-20 |
| PANFIRE-3 Trial: Assessing Safety and Efficacy of Irreversible Electroporation (IRE) + Nivolumab + CpG for Metastatic Pancreatic Cancer (NCT04612530) | Amsterdam UMC, location VUmc | 2020-09-01 |
| A Study of Maintenance Treatment With Fluzoparib in gBRCA/PALB2 Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy (NCT04300114) | Jiangsu HengRui Medicine Co., Ltd. | 2020-08-19 |
| Niraparib + Dostarlimab + RT in Pancreatic Cancer (NCT04409002) | Massachusetts General Hospital | 2020-07-23 |
| Irreversible Electroporation (IRE) Followed by Nivolumab in Patients With Metastatic Pancreatic Cancer. (NCT04212026) | University Hospital, Basel, Switzerland | 2020-06-28 |
| Nivolumab + Ipilimumab + Radiation in MSS Pancreatic Cancer (NCT04361162) | Massachusetts General Hospital | 2020-05-18 |
| Second Line Treatment With Nal-IRI and S1 in Pancreatic Cancer (NCT03986294) | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 2019-12-01 |
| Disulfiram-Copper Gluconate in Met Pancreas Cancer w Rising CA19-9 on Abraxane-Gemzar, FOLFIRINOX or Gemcitabine (NCT03714555) | HonorHealth Research Institute | 2019-10-17 |
| Apatinib, Irinotecan and S-1 (ApaIRIS) in Treating Patients With Metastatic Pancreatic Cancer After AG Regimen (NCT04101929) | Fudan University | 2019-10-01 |
| Efficacy and Safety of Camrelizumab Combined With Nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer (NCT04498689) | Fudan University | 2019-08-01 |
| Multi-center, Open-label, Phase 1b Clinical Trial to Evaluate the Safety, Tolerability, and Exploratory Efficacy of TEW-7197 in Combination With FOLFOX in Patients With Metastatic Pancreatic Ductal Adenocarcinoma Who Have Failed First-Line Gemcitabine and Nab-Paclitaxel (NCT03666832) | Joon Oh Park | 2019-06-17 |
| Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in People With Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer From Colorectal or Pancreatic Cancers (NCT03785210) | National Cancer Institute (NCI) | 2019-06-05 |
| Multimodal Managements for Metastatic Pancreatic Cancer. (NCT06967233) | Zhejiang University | 2019-06-01 |
| High Dose Ascorbic Acid and Nanoparticle Paclitaxel Protein Bound and Cisplatin and Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer (NCT03908333) | Medical College of Wisconsin | 2019-05-01 |
| Pancreatic Cancer Malnutrition and Pancreatic Exocrine Insufficiency in the Course of Chemotherapy in Unresectable Pancreatic Cancer (NCT04112836) | Moscow Clinical Scientific Center | 2019-03-15 |
| A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic Cancer (NCT03816163) | Astellas Pharma Global Development, Inc. | 2019-03-15 |
| Nab-paclitaxel and Gemcitabine in Metastatic Pancreatic Cancer (NCT03929094) | Fudan University | 2019-03-01 |
| Predictive Value of Analysing Tissue From Patients With Metastatic Pancreatic Cancer for Drug Sensitivity (NCT03821870) | Vejle Hospital | 2019-02-25 |
| Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors (NCT03682289) | Rahul Aggarwal | 2019-01-17 |
| High Dose Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer (NCT03797443) | Piedmont Cancer Institute | 2019-01-01 |
| A Study of GB201 in Combination With Weekly Paclitaxel and Low-dose Gemcitabine in Patients With Pancreatic Cancer (NCT03721744) | 1Globe Health Institute LLC | 2018-10-25 |
| EL CENTRO: Engaging Latinos in the Center of Cancer Treatment Options (NCT03602885) | Dana-Farber Cancer Institute | 2018-09-01 |
| Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic Adenocarcinoma (NCT03376659) | Georgetown University | 2018-08-08 |
| QUILT-3.088: NANT Pancreatic Cancer Vaccine (NCT03563144) | ImmunityBio, Inc. | 2018-08-01 |
| Efficacy and Safety of Modified Nab-Paclitaxel Plus Gemcitabine Chemotherapy for Metastatic Pancreatic Cancer (NCT03502343) | Yonsei University | 2018-04-01 |
| 2nd-line Therapy With Nal-IRI After Gem/Nab-pac in Advanced Pancreatic Cancer - Predictive Role of 1st-line Therapy (NCT03468335) | AIO-Studien-gGmbH | 2018-03-31 |
| Post Marketing Surveillance Study for ONIVYDE® in South Korea (NCT03446872) | Institut de Recherches Internationales Servier | 2018-03-08 |
| A Study of ASN007 in Patients With Advanced Solid Tumors (NCT03415126) | Asana BioSciences | 2018-01-19 |
| A SU2C Catalyst® Trial of a PD1 Inhibitor With or Without a Vitamin D Analog for the Maintenance of Pancreatic Cancer (NCT03331562) | Translational Genomics Research Institute | 2017-12-27 |
| A Clinical Trial of Entinostat in Combination With Nivolumab for Patients With Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreatic Adenocarcinoma (NCT03250273) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2017-11-06 |
| A Study to Evaluate the Safety, Tolerability, and Activity of TAK-931 in Participants With Metastatic Pancreatic Cancer, Metastatic Colorectal Cancer, and Other Advanced Solid Tumors (NCT03261947) | Millennium Pharmaceuticals, Inc. | 2017-10-25 |
| A Study of CPI-613 With Gemcitabine and Nab-paclitaxel for Patients With Advanced or Metastatic Pancreatic Cancer (NCT03435289) | Atlantic Health System | 2017-10-19 |
| RX-3117 in Combination With Abraxane® in Subjects With Metastatic Pancreatic Cancer (NCT03189914) | Processa Pharmaceuticals | 2017-10-02 |
| Relationship Between Evolution of Resting Energy Expenditure and Tumoral Response to Chemotherapy in Patients Suffering From Pancreas Cancer (NCT02921646) | Center Eugene Marquis | 2017-07-10 |
| Phase 1 Trial of Interleukin 12 Gene Therapy for Metastatic Pancreatic Cancer (NCT03281382) | Henry Ford Health System | 2017-07-01 |
| A Study of Nab-Paclitaxel and Gemcitabine With or Without Olaratumab (LY3012207) in Participants With Metastatic Pancreatic Cancer (NCT03086369) | Eli Lilly and Company | 2017-06-22 |
| Olaptesed (NOX-A12) Alone and in Combination With Pembrolizumab in Colorectal and Pancreatic Cancer (NCT03168139) | TME Pharma AG | 2017-04-18 |
| First-line Treatment of Metastatic Pancreatic Cancer With Nab-paclitaxel and Gemcitabine (NCT02564146) | AIO-Studien-gGmbH | 2016-12-01 |
| Immune Checkpoint Inhibition in Combination With Radiation Therapy in Pancreatic Cancer or Biliary Tract Cancer Patients (NCT02866383) | Herlev Hospital | 2016-11-01 |
| Afatinib and Gemcitabine/Nab-paclitaxel in Metastatic Pancreatic Cancer (NCT02975141) | PD Dr. med. Volker Heinemann | 2016-09-01 |
| Patient Reported Outcomes Registry in Patient With Cancer Cachexia (NCT02983500) | iOMEDICO AG | 2016-08-28 |
| A One-Arm Exploratory Clinical Trial of Apatinib Plus Gemcitabine in Patients With Advanced Metastatic Pancreatic Cancer (NCT02863367) | Tianjin Medical University Cancer Institute and Hospital | 2016-08-01 |
| A Study of Galunisertib (LY2157299) and Durvalumab (MEDI4736) in Participants With Metastatic Pancreatic Cancer (NCT02734160) | Eli Lilly and Company | 2016-06-15 |
| Phase II of BAX2398/5-FU/Calcium Levofolinate in Pancreatic Cancer (NCT02697058) | Institut de Recherches Internationales Servier | 2016-03-30 |
| Project Survival-Prospective Biomarker Discovery (NCT02781012) | Pancreatic Cancer Research Team | 2016-03-01 |
| Safety and Efficacy of Clopidogrel in Locally Advanced and Metastatic Pancreatic Adenocarcinoma Treated With Chemotherapy (NCT02404363) | Assistance Publique - Hôpitaux de Paris | 2016-01-11 |
| FIrst Line Treatment of Metastatic Pancreatic Cancer: Sequential Nab-paclitaxel + Gemcitabine/FOLFIRI.3 VS Nab-paclitaxel + Gemcitabine (NCT02827201) | Federation Francophone de Cancerologie Digestive | 2015-11-01 |
| Phase 2, Nab Paclitaxel/Gemcitabine Alone and in Combination With ACP-196 in Subjects With Metastatic Pancreatic Cancer (NCT02570711) | Acerta Pharma BV | 2015-10-13 |
| Improving Informed Consent for Palliative Chemotherapy (NCT02282722) | Dana-Farber Cancer Institute | 2015-06-10 |
| Treatment of Pancreatic Cancer With Abraxane (NCT02555813) | Celgene | 2015-05-08 |
| ACP-196 Alone and in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Pancreatic Cancer (NCT02362048) | Acerta Pharma BV | 2015-05-01 |
| First-line Metastatic Pancreatic Cancer : FOLFIRINOX +/- LV5FU2 in Maintenance Versus Firgem (NCT02352337) | Federation Francophone de Cancerologie Digestive | 2015-01-12 |
| Study of Combined SGT-53 Plus Gemcitabine/Nab-Paclitaxel for Metastatic Pancreatic Cancer (NCT02340117) | SynerGene Therapeutics, Inc. | 2015-01-01 |
| BP-C1 in Short-term Treatment of Metastatic Pancreatic Cancer (NCT03627390) | Meabco A/S | 2014-12-19 |
| Observational Study on Quality of Life of Patients Receiving Nab-paclitaxel/Gemcitabine First Line Therapy, Including a Translational Program (NCT02691052) | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 2014-12-01 |
| Evaluation of an Adapted Physical Activity Program in Patients With Unresectable Pancreatic Cancer (NCT02184663) | GERCOR - Multidisciplinary Oncology Cooperative Group | 2014-11-20 |
| Study of IDO Inhibitor in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer (NCT02077881) | NewLink Genetics Corporation | 2014-08-01 |
| BrUOG 292: FOLFOX-A For Metastatic Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial (NCT02080221) | Brown University | 2014-08-01 |
| Feasibility of Biodynamic Imaging for Predicting Therapeutic Effect in Metastatic Adenocarcinoma of the Pancreas (NCT02205788) | Patrick Joseph Loehrer Sr. | 2014-07-01 |
| Phase I Trial of LCL161 and Gemcitabine Plus Nab-Paclitaxel in Metastatic Pancreatic Cancer (NCT01934634) | US Oncology Research | 2014-03-01 |
| Phase I/II Study to Evaluate Nab-paclitaxel in Substitution of CPT11 or Oxaliplatin in FOLFIRINOX Schedule as First Line Treatment in Metastatic Pancreatic Cancer (NCT02109341) | Gruppo Oncologico Italiano di Ricerca Clinica | 2014-02-01 |
| Efficacy of ABI-007 Plus Gemcitabine or sLV5FU2 as First-line Therapy in Patients With Metastatic Pancreatic Cancer (NCT01964534) | GERCOR - Multidisciplinary Oncology Cooperative Group | 2013-12-12 |
| Gemcitabine and Nabpaclitaxel in Metastatic Pancreatic Carcinoma. (NCT03620461) | Galician Research Group on Digestive Tumors | 2013-12-01 |
| Phase 3 Trial of 90Y-Clivatuzumab Tetraxetan & Gemcitabine vs Placebo & Gemcitabine in Metastatic Pancreatic Cancer (NCT01956812) | Gilead Sciences | 2013-12-01 |
| PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Participants With Stage IV Untreated Pancreatic Cancer (NCT01839487) | Halozyme Therapeutics | 2013-05-14 |
| Safety and Efficacy Study of PRI-724 Plus Gemcitabine in Subjects With Advanced or Metastatic Pancreatic Adenocarcinoma (NCT01764477) | Prism Pharma Co., Ltd. | 2013-04-01 |
| mFOLFIRINOX as First-Line Chemotherapy in Treating Chinese Patients With Metastatic Pancreatic Cancer (NCT02028806) | Yuhong Li | 2013-02-01 |
| QYHJ Granules Versus Xeloda in Metastatic Pancreatic Cancer (NCT01796782) | Fudan University | 2013-01-01 |
| BrUOG 278: FOLFOX-A For Pancreatic Cancer A Brown University Oncology Research Group Study (NCT01744353) | Brown University | 2012-11-01 |
| BKM120 + mFOLFOX6 in Advanced Solid Tumors With Expansion Cohort Pancreatic Cancer (NCT01571024) | UNC Lineberger Comprehensive Cancer Center | 2012-05-01 |
| M402 in Combination With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer (NCT01621243) | Momenta Pharmaceuticals, Inc. | 2012-05-01 |
| A Clinical Trial of Anti-Angiogenic Drug Combination Tl-118 for Pancreatic Cancer Patients Who Are Starting Gemcitabine Treatment (NCT01509911) | Tiltan Pharma Ltd. | 2012-01-01 |
| QUILT-3.019: Phase 2 Study of NPC-1C Chimeric Monoclonal Antibody to Treat Pancreatic and Colorectal Cancer (NCT01040000) | Precision Biologics, Inc | 2012-01-01 |
| Gemcitabine and Oxaliplatin in the Management of Metastatic Pancreatic Cancers With Low Expression of ERCC1 (NCT01524575) | University of Hawaii | 2012-01-01 |